TLX · Telix Pharmaceuticals Ltd

🧪 Trial & FDA Catalysts

• Jan 2027 · Phase 3 · Recruiting · PSMA PET Combined With MRI for the Detection of PCa
  Registry primary completion date, not a results date
• Apr 2027 · Phase 1 · Recruiting · Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
  Registry primary completion date, not a results date
• Jun 2027 · Phase 1 · Active Trial · 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
  Registry primary completion date, not a results date
• Jul 2027 · Phase 3 · Recruiting · Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patie
  Registry primary completion date, not a results date
• Aug 2027 · Phase 3 · Recruiting · Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurr
  Registry primary completion date, not a results date
• Oct 2027 · Phase 1 · Recruiting · 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not TLX's own candidates): Enzalutamide, Abiraterone Acetate, Docetaxel Anhydrous, Nivolumab, Cabozantinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TLX holds $251.9M in cash and short-term investments and burns about $3M/quarter from operations, an estimated runway of 251.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

• Cash runway not available

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TLX files for a raise →